Literature DB >> 11342475

Atrial reentrant tachycardia after surgery for congenital heart disease: endocardial mapping and radiofrequency catheter ablation using a novel, noncontact mapping system.

T Paul1, B Windhagen-Mahnert, T Kriebel, H Bertram, R Kaulitz, T Korte, M Niehaus, J Tebbenjohanns.   

Abstract

BACKGROUND: The purpose of the present study was to determine the role of a novel, noncontact mapping system for assessing a variety of atrial reentrant tachycardias (ART) in patients after the surgical correction of congenital heart disease. METHODS AND
RESULTS: In 14 patients, an electrophysiological study using the Ensite 3000 system was performed to assess ARTs resistant to medical treatment. Sixteen different forms of ART were inducible in the 14 patients studied. The reentrant circuit of all ARTs could be characterized and localized with respect to anatomic landmarks such as atriotomy scars, intraatrial patches/baffles, and cardiac structures. In 15 of the 16 ARTs (in 13 of the 14 patients), a target area of the reentrant circuit for radiofrequency current application (ie, an area of conduction between 2 anatomical obstacles such as surgical barriers and cardiac structures of electrical isolation) could be localized within the systemic venous atrium. Nine patients exhibited macroreentry, and 4 showed microreentry. In 12 patients, ART could be terminated by creating linear radiofrequency current lesions (75 degrees C, 180 to 390 s). Completeness of linear lesions after radiofrequency current delivery was proven by analyzing color-coded isopotential maps of atrial activation while applying atrial pacing techniques. The mean duration of the procedures was 286 minutes (range, 130 to 435 minutes); fluoroscopy time ranged from 7 to 33.8 minutes (mean, 17.4 minutes).
CONCLUSIONS: In patients with ART after the surgical correction of congenital heart disease, the use of the noncontact mapping system allows for characterization of the tachycardia and guidance for effective radiofrequency current delivery.

Entities:  

Mesh:

Year:  2001        PMID: 11342475     DOI: 10.1161/01.cir.103.18.2266

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Image-based electrode array tracking for epicardial electrophysiological mapping in minimally invasive arrhythmia surgery.

Authors:  Hongho Kim; Paul de Lange; Takehiro Ando; Sanghyun Joung; Kazuhiro Taniguchi; Hongen Liao; Shunei Kyo; Minoru Ono; Shinichi Takamoto; Etsuko Kobayashi; Ichiro Sakuma
Journal:  Int J Comput Assist Radiol Surg       Date:  2010-05-22       Impact factor: 2.924

2.  Slow pathway ablation in a 5-year-old boy with atrioventricular septal defect: value of cryoenergy application.

Authors:  T Kriebel; H Schneider; M Sigler; T Paul
Journal:  Clin Res Cardiol       Date:  2006-09-28       Impact factor: 5.460

Review 3.  Invasive electrophysiology in paediatric and congenital heart disease.

Authors:  D J Abrams
Journal:  Heart       Date:  2007-03       Impact factor: 5.994

Review 4.  Cell delivery and tracking in post-myocardial infarction cardiac stem cell therapy: an introduction for clinical researchers.

Authors:  Heming Wei; Ting Huay Ooi; Genevieve Tan; Sze Yun Lim; Ling Qian; Philip Wong; Winston Shim
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

5.  Catheter ablation of atrial incisional tachycardia mistaken for atrial flutter.

Authors:  L Ottaviano; C Muto; G Carreras; M Canciello; B Tuccillo
Journal:  Indian Pacing Electrophysiol J       Date:  2007-04-01

Review 6.  [Arrhythmia in adults with congenital heart defects : Atrial tachycardia].

Authors:  Sabine Ernst; Siew Yen Ho; Karen McCarthy
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-06-01

7.  A new approach to the intracardiac inverse problem using Laplacian distance kernel.

Authors:  Raúl Caulier-Cisterna; Sergio Muñoz-Romero; Margarita Sanromán-Junquera; Arcadi García-Alberola; José Luis Rojo-Álvarez
Journal:  Biomed Eng Online       Date:  2018-06-20       Impact factor: 2.819

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.